Flu News and Research

RSS

Legacy Biotechnologies commences production of Reme-Flu

Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies’ unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.

18 Mar 2010

Meta-study: Seven health risks impair academic performance of urban minority youth

"Educationally relevant health disparities" are key drivers of the achievement gap, "but they are largely overlooked," Charles Basch, the Richard March Hoe Professor of Health Education at Teachers College, Columbia University, said at a recent panel discussion at the College.

18 Mar 2010

Modulating body's inflammatory response may help fight serious infection

Treating virulent influenza, sepsis, and other potentially deadly infections long has focused on looking for ways to kill viruses and bacteria. But new research from the University of Utah and Utah State University shows that modulating the body's own overeager inflammatory response to infection may help save more lives.

18 Mar 2010

PPD, Southern Research Institute collaborate in pandemic and seasonal influenza vaccine research

PPD and Southern Research Institute today announced they have formed a collaborative agreement in pandemic and seasonal influenza vaccine research and development to provide clients a full spectrum of influenza vaccine development services by collaborating on client bids and projects.

18 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

ICID provides online planning tools to help non-profit organizations develop pandemic flu plans

On the heels of the recent H1N1 pandemic, the International Centre for Infectious Diseases is providing online planning tools to help non-profit organizations develop pandemic flu plans. It is urging vigilance against future waves of the virus, and advises organizations to take action now to plan for events that could threaten the delivery of service to their clients.

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

Renhuang Pharmaceuticals' net income for first-quarter of 2010 increases 17.8%

Renhuang Pharmaceuticals, Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced its financial results for the first quarter ended January 31, 2010.

17 Mar 2010

Studies examine ways to increase healthcare personnel vaccination rates through social networking

Healthcare personnel influenza immunization rates have remained low, despite recommendations from the Centers for Disease Control and Prevention (CDC) and other leading healthcare organizations that all healthcare personnel receive annual flu vaccines.

17 Mar 2010

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).

16 Mar 2010

Fraunhofer USA CMB receives $4.395M award from DARPA to develop H1N1 influenza vaccine

Fraunhofer USA Center for Molecular Biotechnology announced today that it has received a $4.395 million award from the Defense Advanced Research Projects Agency to develop a vaccine against H1N1 influenza virus using its plant-based production platform.

16 Mar 2010

MRSA Survivors Network urges CDC to declare MRSA an epidemic

MRSA Survivors Network, the nonprofit organization, along with other advocates, urgently plead with the CDC – (Centers for Disease Control and Prevention), along with the Department of Health and Human Services (DHHS) to finally acknowledge the public health crisis to the public and take action.

16 Mar 2010

Obesity limits body's ability to fight infections

Obesity may limit the body's ability to develop immunity to influenza viruses, particularly secondary infections, by inhibiting the immune system's ability to "remember" how it fought off previous similar bouts of illness, according to new research from the University of North Carolina at Chapel Hill.

16 Mar 2010

Opinions: Discrimination against sexual orientation; WFP in Somalia; Haiti's recovery; WHO's policy role

In a Washington Post opinion piece, Desmond Tutu, archbishop emeritus of Cape Town, South Africa, and Nobel Peace Prize recipient, speaks out against efforts to deny individuals "their fundamental rights and freedoms" based on their sexual orientation.

16 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well. The study was conducted to determine if immunized children could act as a barrier to limit the spread of influenza to the wider, unvaccinated community, a concept known as herd immunity.

15 Mar 2010

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Rhesus monkey babies born to mothers who had the flu while pregnant had smaller brains and showed other brain changes similar to those observed in human patients with schizophrenia, a study at the University of Wisconsin-Madison in collaboration with the University of North Carolina at Chapel Hill has found.

12 Mar 2010

Children with chronic illness more likely to develop H1N1 influenza: Study

As critical care professionals develop a better understanding of the progression of H1N1, they are becoming better prepared to treat children with severe cases, according to a new study that will be published in the March issue of Pediatric Critical Care Medicine (PCCM).

12 Mar 2010

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

University of Michigan Health System evaluates factors that can reduce hospital deaths

Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.

9 Mar 2010

Flu News and Research

Legacy Biotechnologies commences production of Reme-Flu

Meta-study: Seven health risks impair academic performance of urban minority youth

Modulating body's inflammatory response may help fight serious infection

PPD, Southern Research Institute collaborate in pandemic and seasonal influenza vaccine research

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

ICID provides online planning tools to help non-profit organizations develop pandemic flu plans

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Renhuang Pharmaceuticals' net income for first-quarter of 2010 increases 17.8%

Studies examine ways to increase healthcare personnel vaccination rates through social networking

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Fraunhofer USA CMB receives $4.395M award from DARPA to develop H1N1 influenza vaccine

MRSA Survivors Network urges CDC to declare MRSA an epidemic

Obesity limits body's ability to fight infections

Opinions: Discrimination against sexual orientation; WFP in Somalia; Haiti's recovery; WHO's policy role

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Children with chronic illness more likely to develop H1N1 influenza: Study

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

University of Michigan Health System evaluates factors that can reduce hospital deaths

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News